THE NEXT BIOLOGIC

Critical insights: the discovery, development, and manufacturing biotherapeutics and vaccines

Welcome to The Next Biologic, the inaugural LinkedIn Newsletter from WuXi Biologics. As a global leader in the biologics drug development industry, we are thrilled to offer a wealth of knowledge, technical content, and valuable resources designed to enhance your understanding and capabilities in biologics discovery, development, and manufacturing. Our mission is to empower your efforts with insights and innovations that enable faster, more efficient, and cost-effective drug development solutions.

What to expect:

The Next Biologic delivers key insights on the cutting-edge technologies and platforms that have propelled WuXi Biologics to the forefront of the industry. From our highly integrated Target to Lead, DNA to IND, and IND to BLA programs to breakthrough advancements in cell line development and bioprocessing, state-of-the-art analytical and characterization methods, and advanced technologies that drive down the cost of goods for manufacturing, we delve into each stage of the biologics pipeline to provide solutions for your everyday challenges. Our experts will share in-depth articles, case studies, and technical guides that demystify complex processes and provide actionable strategies to accelerate your projects.

Featured insights: a novel cell line platform to generate afucosylated antibodies

Increasing the antibody-dependent cell-mediated cytotoxicity (ADCC) response is a crucial mechanism that researchers pursue when applying targeted antibody-based immunotherapy approaches. The development of novel cancer therapies entails designing and engineering antibodies with increased ability to heighten the ADCC response, which improves therapeutic efficacy and patient outcomes.?

Removal of fucose from the N-glycosylation site is an efficient and cost-effective way to enhance ADCC activity and increase the potency of antibody-based immunotherapies. To meet a growing global demand for afucosylated antibodies, we developed the WuXiaADCC PLUS?cell line. Derived from the thoroughly vetted WuXi Biologics WuXia? CHO-K1 cell line, WuXiaADCC PLUS exhibits comparable robust growth and metabolic profile.??

WuXiaADCC PLUS averages an mAb clone titer of 6 g/L and is compatible with the WuXi Biologics cell culture process. The process enables the stable production of afucosylated antibodies at various scales for both clinical and commercial manufacturing.

Contact us to learn more: https://www.wuxibiologics.com/contact-us/

Resource Library:

Visit our Knowledge Center to access the following recent educational and technical resources or browse our full library, which spans the biologics discovery, development, and manufacturing continuum.

Did you know?

GMP cell banking is a crucial process of biopharmaceutical development, significantly influencing the entire chemistry, manufacturing, and controls (CMC) lifecycle. A high-quality, regulatory-compliant, and well-stored cell bank is essential for maintaining a secure, reliable supply of the producer cell line for process development activities, clinical trials, and commercial production.

At WuXi Biologics, we are committed to supporting your biopharmaceutical pipeline with comprehensive and rapid cGMP cell banking, testing, and storage services for mammalian cell lines. To learn more, visit https://www.wuxibiologics.com/capabilities/cell-banking/.

Let’s Stay Connected!

We invite you engage with our community of like-minded professionals dedicated to advancing the biologics landscape. Together, let's harness the power of WuXi Biologics expertise and technology to transform the future of healthcare. Welcome to "The Next Biologic" – where innovation meets inspiration.